Our experimental evidence together with literature data indicate that macitentan may also target both tumor and BM microenvironment, as ET-1 axis drives autocrine and paracrine pro-survival and pro-angiogenic signals in both malignant PCs and ECs. Here, EDN1 is linked to neoplasm.